3International Myeloma Working Group. Criteria for classification of monoclonal gammopathies, multiple myeloma and related disorder: report of the International Myeloma Working Group [J]. Br J Haematol, 2003, 121(5): 749-57.
4LeCouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey[J ]. Br J Haematol, 1999, 106(1): 35-9.
5Horger M, Kanz L, Denecke B, et al. The benefit of using wholebody, low-dose, nonenhanced, multidetector computed tomography for follow up and therapy response monitoring in patients with multiple myeloma[J]. Cancer, 2007, 109(8): 1617-26.
3Yuji Nishiyama,Ukihide Tateishi,Kazuya Shizukuishi,Ayako Shishikura,Etsuko Yamazaki,Hiroto Shibata,Tomohiro Yoneyama,Yoshiaki Ishigatsubo,Tomio Inoue.Role of 18 F-fluoride PET/CT in the assessment of multiple myeloma: initial experience[J]. Annals of Nuclear Medicine . 2013 (1)
4P. Spinnato,A. Bazzocchi,A. Brioli,C. Nanni,E. Zamagni,U. Albisinni,M. Cavo,S. Fanti,G. Battista,E. Salizzoni.Contrast enhanced MRI and 18 F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease[J]. European Journal of Radiology . 2012 (12)
